Status:

RECRUITING

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

Lead Sponsor:

Edwards Lifesciences

Conditions:

Aortic Stenosis, Calcific

Aortic Valve Stenosis

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcifi...

Detailed Description

This is a prospective, randomized, controlled, multicenter study. Subjects will be randomized to either transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 / SAPIEN 3 Ultra /SAPIEN 3 Ultra...

Eligibility Criteria

Inclusion

  • Key
  • 65 years of age or older at time of randomization
  • Moderate aortic stenosis
  • Subject has symptoms or evidence of cardiac damage/dysfunction
  • The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent.
  • Key

Exclusion

  • Native aortic annulus size unsuitable for the THV
  • Anatomical characteristics that would preclude safe transfemoral placement of the introducer sheath or safe passage of the delivery system
  • Aortic valve is unicuspid or non-calcified
  • Bicuspid aortic valve with an aneurysmal ascending aorta \> 4.5 cm or severe raphe/leaflet calcification
  • Pre-existing mechanical or bioprosthetic aortic valve
  • Severe aortic regurgitation
  • Prior balloon aortic valvuloplasty to treat severe AS
  • LVEF \< 20%
  • Left ventricular outflow tract calcification that would increase the risk of annular rupture or significant paravalvular leak post-TAVR
  • Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation
  • Coronary or aortic valve anatomy that increases the risk of coronary artery obstruction post-TAVR

Key Trial Info

Start Date :

October 12 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2037

Estimated Enrollment :

2250 Patients enrolled

Trial Details

Trial ID

NCT04889872

Start Date

October 12 2021

End Date

June 1 2037

Last Update

December 17 2025

Active Locations (80)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 20 (80 locations)

1

Heart Center LLC, Huntsville

Huntsville, Alabama, United States, 35801

2

Tucson Medical Center

Tucson, Arizona, United States, 85712

3

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

4

Huntington Hospital

Pasadena, California, United States, 91105